&Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

&Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$668K	Sell	2,274 -65	-3%	-$18.4K	﹤0.01%	1667
2026 Q1	$645K	Buy	2,339 +76	+3%	+$21.9K	﹤0.01%	1550
2025 Q4	$686K	Sell	2,263 -105	-4%	-$32.8K	﹤0.01%	1445
2025 Q3	$664K	Buy	2,368 +143	+6%	+$38.9K	﹤0.01%	1294
2025 Q2	$535K	Buy	2,225 +365	+20%	+$86.3K	﹤0.01%	1323
2025 Q1	$452K	Buy	1,860 +152	+9%	+$45.7K	﹤0.01%	1184
2024 Q4	$564K	Buy	1,708 +134	+9%	+$45.5K	0.01%	1031
2024 Q3	$527K	Buy	+1,574	New	+$500K	0.01%	848

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

&Partners's BIO Position: Q2 2026 in Review

&Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.8% in Q2 2026, selling an estimated $18.4K and leaving 2,274 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

&Partners first reported a position in BIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $686K in Q4 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

&Partners held 2,274 shares of Bio-Rad Laboratories Class A worth $668K as of Q2 2026.
&Partners sold 65 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $18.4K.
Bio-Rad Laboratories Class A made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1667 holding.
&Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 8 quarters since.
&Partners's Bio-Rad Laboratories Class A position peaked at $686K in Q4 2025.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.